Your browser doesn't support javascript.
loading
Tumor ENPP1 (CD203a)/Haptoglobin Axis Exploits Myeloid-Derived Suppressor Cells to Promote Post-Radiotherapy Local Recurrence in Breast Cancer.
Ruiz-Fernández de Córdoba, Borja; Moreno, Haritz; Valencia, Karmele; Perurena, Naiara; Ruedas, Pablo; Walle, Thomas; Pezonaga-Torres, Alberto; Hinojosa, Juan; Guruceaga, Elisabet; Pineda-Lucena, Antonio; Abengózar-Muela, Marta; Cochonneau, Denis; Zandueta, Carolina; Martínez-Canarias, Susana; Teijeira, Álvaro; Ajona, Daniel; Ortiz-Espinosa, Sergio; Morales, Xabier; Ortiz de Solórzano, Carlos; Santisteban, Marta; Ramos-García, Luis I; Guembe, Laura; Strnad, Vratislav; Heymann, Dominique; Hervás-Stubbs, Sandra; Pío, Rubén; Rodríguez-Ruiz, María E; de Andrea, Carlos E; Vicent, Silvestre; Melero, Ignacio; Lecanda, Fernando; Martínez-Monge, Rafael.
Afiliação
  • Ruiz-Fernández de Córdoba B; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Moreno H; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Valencia K; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Perurena N; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
  • Ruedas P; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Walle T; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Pezonaga-Torres A; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Hinojosa J; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Guruceaga E; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Pineda-Lucena A; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Abengózar-Muela M; Bioinformatics Core Facility, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Cochonneau D; Program of Molecular Therapies, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Zandueta C; Departament of Pathology, Clínica University of Navarra, Pamplona, Spain.
  • Martínez-Canarias S; Nantes Université, CNRS, US2B, UMR 6286, Nantes, France.
  • Teijeira Á; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine, Saint Herblain, France.
  • Ajona D; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Ortiz-Espinosa S; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Morales X; Immunology and Immunotherapy, CIMA, Pamplona, Spain.
  • Ortiz de Solórzano C; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Santisteban M; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
  • Ramos-García LI; Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain.
  • Guembe L; IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
  • Strnad V; Solid Tumors Program. Division of Oncology, Center for Applied Medical Research, University of Navarra (CIMA), Pamplona, Spain.
  • Heymann D; Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
  • Hervás-Stubbs S; Image Core Facility, CIMA, Pamplona, Spain.
  • Pío R; Image Core Facility, CIMA, Pamplona, Spain.
  • Rodríguez-Ruiz ME; Oncology, Clínica University of Navarra, Pamplona, Spain.
  • de Andrea CE; Radiation Oncology, Clínica University of Navarra, Pamplona, Spain.
  • Vicent S; Morphology Core Facility, CIMA, Pamplona, Spain.
  • Melero I; Department of Radiation Oncology, University of Erlangen, Erlangen, Germany.
  • Lecanda F; Nantes Université, CNRS, US2B, UMR 6286, Nantes, France.
  • Martínez-Monge R; Institut de Cancérologie de l'Ouest, Tumor Heterogeneity and Precision Medicine, Saint Herblain, France.
Cancer Discov ; 12(5): 1356-1377, 2022 05 02.
Article em En | MEDLINE | ID: mdl-35191482
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Células Supressoras Mieloides Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Células Supressoras Mieloides Tipo de estudo: Prognostic_studies Limite: Female / Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Espanha